A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

Por Csonka, Denes, Hazell, Katharine, Waldron, Edward, Lorenzo, Sebastien, Duval, Vincent, Trandafir, Lucia, Kobalava, Zhanna D.
Publicado no J Clin Pharmacol (2016)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Por Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Publicado no Onco Targets Ther (2016)

ATNT-12 PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND...

Por Rodon, Jordi, Rosenthal, Mark, Mason, Warren, Segura, Pedro Perez, Beck, Joseph T., Hirte, Holger, DeGroot, John F., Trandafir, Lucia, Pognan, Nathalie, Yang, Lin, Kanwal, Charu, Wen, Patrick Y.
Publicado no Neuro Oncol (2015)

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases...

Por Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.
Publicado no Prostate (2019)